For patients receiving concurrent drug therapy, it is imperative to consider the presence of other P-gp and CYP3A4 inhibitors, such as Diltiazem, fluconazole, Azithromycin, carvedilol, verapamil, etc., as they have the potential to impact statin and colchicine concentrations thereby increasing the risk of myopathy (Schwier et al., 2022). The gene discussed is CYP3A4; the disease is myopathy.